Clinical Trial Update: SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is planned to compare SYS6002 with PADCEV (enfortumab vedotin) in adults with advanced urothelial carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Padcev (enfortumab vedotin)
• SYS6002

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Advanced Urothelial Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING